In this study we investigated the expression of CK2α and CK2β in a panel of HL cell lines and HL patient samples, analyzed CK2 mediated activation of survival signaling pathways and investigated the capability of inhibiting CK2 with the ATP-competitive inhibitor CX-4945/Silmitasertib along with MMAE to trigger HRS cell apoptosis and assess PD-L1 expression levels. This evidence concerns the gene CSNK2B and Hodgkins lymphoma.